Nyström Johanna, Raghavan S, Svennerholm A-M
Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute, Göteborg University, Box 435, 405 30 Göteborg, Sweden.
Microbes Infect. 2006 Feb;8(2):442-9. doi: 10.1016/j.micinf.2005.07.010. Epub 2005 Sep 22.
The aim of this study was to investigate the capacity of oral and parenteral therapeutic immunization to reduce the bacterial colonization in the stomach after experimental Helicobacter pylori infection, and to evaluate whether any specific immune responses are related to such reduction. C57BL/6 mice were infected with H. pylori and thereafter immunized with H. pylori lysate either orally together with cholera toxin or intraperitoneally (i.p.) together with alum using immunization protocols that previously have provided prophylactic protection. The effect of the immunizations on H. pylori infection was determined by quantitative culture of H. pylori from the mouse stomach. Mucosal and systemic antibody responses were analyzed by ELISA in saponin extracted gastric tissue and serum, respectively, and mucosal CD4+ T cell responses by an antigen specific proliferation assay. Supernatants from the proliferating CD4+ T cells were analyzed for Th1 and Th2 cytokines. The oral, but not the parenteral therapeutic immunization induced significant decrease in H. pylori colonization compared to control infected mice. The oral immunization resulted in markedly elevated levels of serum IgG+M as well as gastric IgA antibodies against H. pylori antigen and also increased H. pylori specific mucosal CD4+ T cell proliferation with a Th1 cytokine profile. Although the parenteral immunization induced dramatic increases in H. pylori specific serum antibody titers, no increases in mucosal antibody or cellular immune responses were observed after the i.p. immunization compared to control infected mice. These findings suggest that H. pylori specific mucosal immune responses with a Th1 profile may provide therapeutic protection against H. pylori.
本研究的目的是调查口服和肠胃外治疗性免疫在实验性幽门螺杆菌感染后减少胃部细菌定植的能力,并评估是否有任何特异性免疫反应与这种减少相关。将C57BL/6小鼠感染幽门螺杆菌,然后使用先前已提供预防性保护的免疫方案,用幽门螺杆菌裂解物与霍乱毒素一起口服或与明矾一起腹腔内(i.p.)免疫。通过对小鼠胃部幽门螺杆菌进行定量培养来确定免疫对幽门螺杆菌感染的影响。分别通过ELISA分析皂苷提取的胃组织和血清中的粘膜和全身抗体反应,并通过抗原特异性增殖试验分析粘膜CD4+T细胞反应。分析增殖的CD4+T细胞的上清液中的Th1和Th2细胞因子。与对照感染小鼠相比,口服而非肠胃外治疗性免疫导致幽门螺杆菌定植显著减少。口服免疫导致血清IgG+M以及针对幽门螺杆菌抗原的胃IgA抗体水平显著升高,并且还增加了具有Th1细胞因子谱的幽门螺杆菌特异性粘膜CD4+T细胞增殖。尽管肠胃外免疫导致幽门螺杆菌特异性血清抗体滴度急剧增加,但与对照感染小鼠相比,腹腔内免疫后未观察到粘膜抗体或细胞免疫反应增加。这些发现表明,具有Th1谱的幽门螺杆菌特异性粘膜免疫反应可能提供针对幽门螺杆菌的治疗性保护。